We are a biotechnology company focused on the development of novel surfactant replacement therapies with broad potential application across many respiratory diseases. Surfactant is essential for normal breathing throughout life. Our fully-synthetic surfactant technology platform has the potential to establish a completely new therapeutic approach for the treatment of respiratory disease, with a targeted initial application in preterm infants.

Our Mission

Our company has one focused goal – to create life-saving medications for patients with respiratory disease in order to advance the standard of care for pulmonary medicine. We will provide our dedicated employees with a rewarding work experience, work side-by-side with the healthcare community and create value for our shareholders.

Recent News

January 2012 Corporate Presentation

Dec 6, 2011
New Study Shows AFECTAIR® Significantly Improved Delivery of Nitric Oxide Under Simulated Neonatal Ventilatory Conditions

Nov 11, 2011
Discovery Labs to Present at the Lazard Capital Markets Healthcare Conference

Nov 10, 2011
Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs Click here to listen

Nov 8, 2011
Discovery Labs Releases New AFECTAIR^TM Performance Data Presented at the American Association for Respiratory Care Annual Meeting

Nov 3, 2011
Discovery Labs’ KL₄ Surfactant Granted Orphan Drug Designation in Europe for the Treatment of Cystic Fibrosis

Nov 2, 2011
Discovery Labs AFECTAIR^TM Technology to Be Presented at the American Association for Respiratory Care Annual Meeting